153 related articles for article (PubMed ID: 30862694)
41. PAK1 and PAK2 have different roles in HGF-induced morphological responses.
Bright MD; Garner AP; Ridley AJ
Cell Signal; 2009 Dec; 21(12):1738-47. PubMed ID: 19628037
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Eur J Pharmacol; 2020 Apr; 872():172953. PubMed ID: 31996318
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4.
Li Z; Li X; Xu L; Tao Y; Yang C; Chen X; Fang F; Wu Y; Ding X; Zhao H; Li M; Qian G; Xu Y; Ren J; Du W; Wang J; Lu J; Hu S; Pan J
Oncol Rep; 2017 Nov; 38(5):2705-2716. PubMed ID: 29048629
[TBL] [Abstract][Full Text] [Related]
44. Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.
Chang Y; Park KH; Lee JE; Han KC
Biochem Biophys Res Commun; 2018 Oct; 505(1):187-193. PubMed ID: 30243723
[TBL] [Abstract][Full Text] [Related]
45. Clinicopathologic features of adult T-cell leukemias/lymphomas at a North American tertiary care medical center: infrequent involvement of the central nervous system.
Hsi AC; Kreisel FH; Frater JL; Nguyen TT
Am J Surg Pathol; 2014 Feb; 38(2):245-56. PubMed ID: 24418858
[TBL] [Abstract][Full Text] [Related]
46. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
47. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
48. Butein inhibits NF-κB, AP-1 and Akt activation in adult T-cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2017 Aug; 51(2):633-643. PubMed ID: 28586006
[TBL] [Abstract][Full Text] [Related]
49. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL).
Hatta Y; Koeffler HP
Leukemia; 2002 Jun; 16(6):1069-85. PubMed ID: 12040438
[TBL] [Abstract][Full Text] [Related]
50. p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma.
Qasim SL; Sierra L; Shuck R; Kurenbekova L; Patel TD; Rajapakshe K; Wulff J; Nakahata K; Kim HR; Landesman Y; Unger TJ; Coarfa C; Yustein JT
Oncogene; 2021 Feb; 40(6):1176-1190. PubMed ID: 33414491
[TBL] [Abstract][Full Text] [Related]
51. Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma.
Nadella MV; Dirksen WP; Nadella KS; Shu S; Cheng AS; Morgenstern JA; Richard V; Fernandez SA; Huang TH; Guttridge D; Rosol TJ
Leukemia; 2007 Aug; 21(8):1752-62. PubMed ID: 17554373
[TBL] [Abstract][Full Text] [Related]
52. Association of p21-activated kinase-1 activity with aggressive tumor behavior and poor prognosis of head and neck cancer.
Park J; Kim JM; Park JK; Huang S; Kwak SY; Ryu KA; Kong G; Park J; Koo BS
Head Neck; 2015 Jul; 37(7):953-63. PubMed ID: 24634274
[TBL] [Abstract][Full Text] [Related]
53. Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer.
Zhao CC; Zhan MN; Liu WT; Jiao Y; Zhang YY; Lei Y; Zhang TT; Zhang CJ; Du YY; Gu KS; Wei W
Cancer Lett; 2020 Nov; 493():120-127. PubMed ID: 32829006
[TBL] [Abstract][Full Text] [Related]
54. Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion.
Siu MK; Wong ES; Chan HY; Kong DS; Woo NW; Tam KF; Ngan HY; Chan QK; Chan DC; Chan KY; Cheung AN
Int J Cancer; 2010 Jul; 127(1):21-31. PubMed ID: 19876919
[TBL] [Abstract][Full Text] [Related]
55. Targeting p21-activated kinase 1 inhibits growth and metastasis via Raf1/MEK1/ERK signaling in esophageal squamous cell carcinoma cells.
Chen L; Bi S; Hou J; Zhao Z; Wang C; Xie S
Cell Commun Signal; 2019 Apr; 17(1):31. PubMed ID: 30971268
[TBL] [Abstract][Full Text] [Related]
56. PAK1 overexpression promotes myxofibrosarcoma angiogenesis through STAT5B-mediated
Li CF; Chan TC; Fang FM; Yu SC; Huang HY
Int J Biol Sci; 2023; 19(12):3920-3936. PubMed ID: 37564209
[TBL] [Abstract][Full Text] [Related]
57. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.
Shah UA; Chung EY; Giricz O; Pradhan K; Kataoka K; Gordon-Mitchell S; Bhagat TD; Mai Y; Wei Y; Ishida E; Choudhary GS; Joseph A; Rice R; Gitego N; Parrish C; Bartenstein M; Goel S; Mantzaris I; Shastri A; Derman O; Binder A; Gritsman K; Kornblum N; Braunschweig I; Bhagat C; Hall J; Graber A; Ratner L; Wang Y; Ogawa S; Verma A; Ye BH; Janakiram M
Blood; 2018 Oct; 132(14):1507-1518. PubMed ID: 30104217
[TBL] [Abstract][Full Text] [Related]
58. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
[TBL] [Abstract][Full Text] [Related]
59. miR-137 inhibits proliferation of melanoma cells by targeting PAK2.
Hao S; Luo C; Abukiwan A; Wang G; He J; Huang L; Weber CE; Lv N; Xiao X; Eichmüller SB; He D
Exp Dermatol; 2015 Dec; 24(12):947-52. PubMed ID: 26186482
[TBL] [Abstract][Full Text] [Related]
60. The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin.
Prudnikova TY; Chernoff J
Small GTPases; 2017 Oct; 8(4):193-198. PubMed ID: 27427770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
